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A phase 2 randomised controlled trial of
serelaxin to lower portal pressure in
cirrhosis (STOPP)
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Abstract
Background: In preclinical models, recombinant human relaxin-2 (serelaxin) had anti-fibrotic effects and
ameliorated portal hypertension (PH). A small exploratory study in patients with cirrhosis also suggested that
serelaxin could reduce portal pressure.
Methods: In a phase 2, double-blind, randomised controlled study conducted in a single centre (Royal Infirmary of
Edinburgh, UK), male and female adult participants with cirrhosis and clinically significant PH (CSPH; hepatic venous
pressure gradient (HVPG) > 10 mmHg) were enrolled. Participants were allocated to serelaxin or placebo in a 3:1
ratio. The placebo was matched to serelaxin on appearance and administration protocol to create and maintain
blinding. The primary endpoint was the change from baseline in fasting HVPG after 2 h of peripheral i.v. serelaxin
infusion (80 μg/kg/day for 60 min followed by 30 μg/kg/day for at least 60 min). Secondary endpoints included the
change from baseline in hepatic blood flow and systemic haemodynamics (cardiac index, systemic vascular
resistance index and aortic pulse wave velocity). Short-term safety and tolerability of serelaxin were assessed.
Results: A total of 17 participants were screened, 15 were randomised and 11 completed the study (n = 9 serelaxin,
n = 2 placebo). Reasons for withdrawal were baseline HVPG < 10 mmHg (n = 2) and technical failure (n = 2). The
trial ended early due to manufacturer discontinuation of the study drug. The median age was 56 (range 43–69)
years and 73% of participants were male. Alcohol was the commonest cirrhosis aetiology (n = 10). Participants had
a median Model for End-Stage Liver Disease score of 10 (range 6–14). The mean baseline HVPG was 16.3 (range
10.3–21.7) mmHg. Individual responses were variable, but overall there was no statistically significant change in
HVPG after 2 h of i.v. serelaxin (arithmetic mean of difference ± SD was 0.4 ± 3.5 mmHg (95% CI –2.3, 3.1; p = 0.76)).
There were also no substantial changes from baseline in hepatic or systemic haemodynamics. We recorded 12
adverse events in 7 participants treated with serelaxin; none were significant, and most were unrelated to the
investigational medicinal product. There were no serious adverse events.
Conclusion: In a small randomised, phase 2, proof-of-concept study in patients with cirrhosis and CSPH, serelaxin
infusion was safe and well-tolerated but had a neutral effect on HVPG.
Trial registration: ClinicalTrials.gov, NCT02669875. Registered on 1 February 2016.
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Background
Standardised mortality rates for liver disease in the UK
have increased 400% since 1970, and in people younger
than age 65 years have increased by almost 500% [1]. In
patients with cirrhosis of the liver, portal hypertension
(PH) is the main cause of death and of liver transplant-
ation. In Europe alone, it is estimated that 29 million pa-
tients suffer from chronic liver disease, and that 170,000
die each year from complications of cirrhosis, a number
exceeding the mortality due to breast cancer [2]. Patients
with hepatic venous pressure gradient (HVPG) ≥ 10
mmHg (clinically significant PH, CSPH) are at increased
risk of hepatic decompensation [3] and of hepatocellular
carcinoma [4]. Variceal bleeding occurs when the HVPG
is > 12mmHg. A reduction in the HVPG to < 12mmHg
or by > 20% from baseline is reported to improve clinical
outcomes and represent targets for haemodynamic re-
sponse in interventional studies [5]. Despite a significant
improvement in outcomes over the past 30 years, the aver-
age 6-week mortality for the first episode of variceal bleed-
ing in most studies is reported to be up to 20% [6].
Terlipressin, a synthetic analogue of vasopressin, has an
immediate systemic vasoconstrictor action followed by
portal haemodynamic effects due to slow conversion to
vasopressin. It is the only pharmacological agent used in
acute variceal bleeding that has been shown to reduce
mortality in placebo-controlled trials [6]. Terlipressin de-
creases failure of initial haemostasis by 34%, decreases
mortality by 34% and is considered a first-line treatment
for bleeding oesophageal varices, when available. However,
off-target effects include peripheral and coronary ischae-
mia, and adverse events (AEs) occur in 10–20% of patients
[7]. Terlipressin is not licensed in the USA, where octreo-
tide (a somatostatin analogue) is most commonly used.
Octreotide is also thought to act as a mesenteric arterial
vasoconstrictor, but in an acute haemodynamic study,
octreotide was found to only transiently reduce HVPG
and portal venous flow [8]. Nevertheless, octreotide has
recently been shown to be as effective as terlipressin in
the control of acute variceal bleeding [9].
We have previously shown that serelaxin, a recombinant
form of the human peptide hormone relaxin-2, had anti-
fibrotic and portal hypotensive effects in cirrhotic rats [10].
Moreover, serelaxin reduced the portal pressure by de-
creasing intrahepatic vascular resistance (IHVR) through
augmentation of nitric oxide (NO) bioavailability and sig-
nalling, thus maintaining or enhancing hepatic blood flow.
In a recent small, exploratory, open-label, phase 2 study
[11], Part B showed that serelaxin induced a rapid and po-
tentially clinically significant reduction in portal pressure
in patients with cirrhosis, PH and a transjugular intrahepa-
tic portosystemic shunt (TIPSS). Following at least 120
min of serelaxin infusion there was a 31.3% (95% CI –66.5,
71.6) reduction in the portal pressure gradient (PPG)
compared to baseline. During the infusion there was a pro-
gressive reduction in the portal vein pressure (PVP), reach-
ing a decrease of 25.2% (95% CI –12.7, 50.3) from baseline
at the 120-min time point. The reduction in PVP started
at 30min and continued through to the 135-min time
point. With serelaxin infusion, there were no newly occur-
ring liver enzyme abnormalities, no clinically significant
changes in blood pressure and no discontinuations due to
AEs. Indeed, in a separate study, the pharmacokinetic and
safety profiles of serelaxin were not affected in patients
with mild, moderate or severe hepatic impairment [12].
The objective of this double-blind, randomised
placebo-controlled study was to evaluate, for the first
time, the safety and efficacy of serelaxin in reducing the
portal pressure, as determined by the HVPG in patients
with cirrhosis and CSPH.
Methods
Study participants
We enrolled male or female adult participants over the age
of 18 years with cirrhosis and PH. Full eligibility criteria are
listed in Additional file 1. The main inclusion criteria in-
cluded: clinically diagnosed or biopsy-proven liver cirrhosis
of any aetiology; evidence of PH either on imaging or on
previous endoscopy; and suspected HVPG ≥ 10mmHg at
baseline (if the baseline HVPG was subsequently found to
be < 10mmHg, the participant was withdrawn from the
study). The main exclusion criteria included: pregnancy or
breast-feeding; women of child-bearing potential not using
highly effective methods of contraception; severe liver fail-
ure; history of variceal bleed within the previous month; he-
patocellular carcinoma or history of malignancy of any
organ system (other than localised basal cell carcinoma of
the skin); portal vein thrombosis; previous surgical shunt or
TIPSS; current use of beta-blockers or nitrates, or any other
drug therapy known to have an influence on portal pres-
sure (diuretics were permitted provided patients had been
on a stable dose for at least 30 days); history of active/recent
drug or alcohol abuse; sitting systolic blood pressure < 110
mmHg at screening visit or within 10min prior to starting
study drug infusion; significant arrhythmias, including pro-
longed QT interval; documented hypersensitivity to i.v.
contrast agents and/or iodine; severe renal impairment; sig-
nificant structural heart disease (including cardiomyopathy,
valvular disease); major neurologic events, including cere-
brovascular events, within the previous month; clinical evi-
dence of acute coronary syndrome currently or within the
previous month; and pacemaker, cardiac resynchronisation
device or implantable cardioverter-defibrillator in situ.
Data collection
This was a single-site study, undertaken at the Royal In-
firmary of Edinburgh, Edinburgh, UK between 19 Octo-
ber 2017 and 15 August 2018.
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Participants attended the RIE Clinical Research Facility
for screening (visit 1) consisting of a physical examin-
ation, blood tests (full blood count, coagulation and bio-
chemistry), electrocardiogram (ECG), blood pressure
measurement and written informed consent. Randomisa-
tion was performed once it was known that the partici-
pant had passed screening, prior to the study visit.
On the study day (visit 2; ≤ 7 days after the screening
visit), eligible participants attended for baseline haemo-
dynamic measurements, following an overnight fast and
the avoidance of caffeine for > 8 h. After baseline evalu-
ation and confirmation of HVPG ≥ 10mmHg, participants
received (in a double-blind fashion) either serelaxin or pla-
cebo. The haemodynamic measurements were repeated at
specified time points. A peripheral blood sample was taken
at baseline and after 2 h, processed and stored for potential
future analysis. After the post-treatment assessments, par-
ticipants were observed for a recovery period of 4 h which
included repeat physical examination, blood pressure,
ECG measurement and routine laboratory blood tests.
There was no follow-up visit. Participants were contacted
by a member of the research team via telephone at 24 h
and again at 4 weeks after the study visit to collect infor-
mation about potential AEs and concomitant medications.
Study data were collected and managed using REDCap
electronic data capture tools hosted at The University of
Edinburgh. REDCap [13] (Research Electronic Data Cap-
ture) is a secure, web-based application designed to sup-
port data capture for research studies, providing: an
intuitive interface for validated data entry; audit trails for
tracking data manipulation and export procedures; auto-
mated export procedures for seamless data downloads to
common statistical packages; and procedures for import-
ing data from external sources.
Study design, randomisation and allocation concealment
This study was a phase 2, double-blind, randomised con-
trolled trial to investigate the effects of serelaxin on PH
in patients with cirrhosis. Randomisation was carried
out by an independent third party (Edinburgh Clinical
Trials Unit) after it was confirmed that the participant
had passed screening, prior to the study visit (visit 2).
Random sequences of block sizes were generated by
computer to achieve a 3:1 allocation ratio between sere-
laxin and placebo; there was no stratification to this allo-
cation. Randomisation produced a four-digit integer
matching a bottle number held by the pharmacy. The
Investigators had no way of linking the drug allocation
to the four-digit number. The person generating the ran-
domisation list and allocation concealment was not in-
volved in the later implementation of the sequence. The
original randomisation list was held in a secure folder
with restricted access to the Edinburgh Clinical Trials
Unit Data Management team. The placebo was matched
to serelaxin on appearance and administration protocol
to create and maintain blinding.
Sample size
The primary efficacy endpoint was the decrease in the
fasting HVPG between baseline and 2 h post serelaxin
treatment, targeting for a 20% reduction. The sample
size calculation was based on a previous study in Edin-
burgh evaluating carvedilol [14] and the data from the
previous Novartis-sponsored serelaxin phase 2 study
(ClinicalTrials.gov identifier: NCT01640964) [11]. As-
suming a mean baseline HVPG of 16.37 (SD = 2.14)
mmHg and a post-baseline HVPG of 13.1 (SD = 3.91)
mmHg (20% decrease), the change from baseline in the
HVPG was estimated to be 3.3 (SD = 4) mmHg. A sam-
ple size of 14 participants in the serelaxin group would
provide 80% power to detect at least a 20% decrease
from baseline in HVPG using a two-sided paired t test
with an α level of 0.05. A small number of placebo-
treated patients were included in order to preserve
double-blindness, not as a comparison group. Therefore,
it was proposed that a total of 20 patients (15 serelaxin
and 5 placebo) would be randomised in a 3:1 ratio.
Intervention
Recombinant human relaxin-2 (serelaxin; Novartis Phar-
maceuticals, UK) or placebo (20 mM sodium acetate
buffer solution at pH 5.0; Novartis Pharmaceuticals, UK)
were administered via peripheral i.v. infusion at two dif-
ferent infusion rates: 80 μg/kg/day for 60 min followed
by 30 μg/kg/day for at least 60 min (until completion of
the final HVPG/ICG measurements). This was achieved
by a single infusion bag, prepared by the clinical trials
pharmacist, with a uniform change in the administration
rate.
Study endpoints
The primary endpoint was the change from baseline in
the fasting HVPG after 2 h of serelaxin infusion. The
HVPG was measured as previously described [14]. The
procedure was performed after overnight fast and at the
same time of day due to circadian variation in HVPG
measurements. Prior to catheter insertion, participants
were offered low-dose (≤ 0.02 mg/kg) midazolam to re-
duce any anxiety. A 7-F venous introducer was inserted
into the right femoral vein using the Seldinger technique
under ultrasound guidance. A balloon-tipped catheter
was then advanced into a hepatic vein using fluoroscopy.
The free hepatic venous pressure (FHVP) was measured
with the balloon deflated and floating freely in the hep-
atic vein close to its junction with the inferior vena cava
(IVC). The wedged hepatic venous pressure (WHVP)
was measured with the balloon inflated until the branch
of hepatic vein was completely occluded. The HVPG
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was obtained by subtracting the FHVP from the WHVP.
All measurements were performed in triplicate and per-
manent tracings were printed, stored and read blindly at
the end of the study prior to the opening of the random-
isation codes. The HVPG was measured at baseline, and
then repeated after 60 and 120 min of the IMP (either
serelaxin or placebo). Baseline HVPG ≥ 10mmHg con-
firmed the presence of CSPH. If HVPG < 10mmHg was
obtained, the study participant was withdrawn. The IVC
pressure (IVCP) was measured at baseline and after the
final HVPG measurement.
Secondary endpoints included: the change from base-
line in the fasting HVPG after 1 h of serelaxin infusion;
the change from baseline in the fasting hepatic blood
flow (HBF) after 2 h of serelaxin infusion (measured
from the concentration of indocyanine green (ICG) in
the hepatic venous blood vs peripheral venous blood
using the Fick Principle); the change from baseline in
the IVCP after 2 h of serelaxin infusion; the change from
baseline in the cardiac index (CI) after 2 h of serelaxin
infusion; the change from baseline in the systemic vascu-
lar resistance index (SVRI) after 2 h of serelaxin infusion;
the change from baseline in the aortic pulse wave vel-
ocity after 2 h of serelaxin infusion; safety and tolerabil-
ity of serelaxin infusion (as assessed throughout the
study by monitoring AEs, clinical laboratory blood tests,
heart rate, blood pressure and ECG); and the change
from baseline in exploratory blood biomarker measure-
ments after 2 h of serelaxin infusion (if a demonstrable
effect on the HVPG was observed).
The total HBF was calculated using the ICG constant
infusion method [15, 16] and derived from measure-
ments of ICG clearance and extraction. Baseline serum
samples were taken prior to each ICG infusion. There-
after, 10 mg of ICG (10 ml) was given as a slow i.v. bolus
via a peripheral cannula, followed by an infusion of 0.2
mg/min (0.2 ml/min or 12ml/h) by accurate infusion
pump (Alaris Asena, Becton Dickinson, USA). After an
equilibrium period of at least 40 min, samples were
taken simultaneously from the right hepatic vein (via the
catheter tip) and the femoral vein (via the side port of
the introducer). Paired samples (hepatic and femoral)
were taken in triplicate, 2 min apart, in order to confirm
equilibrium. The HBF was measured in this way both at
baseline and after 120 min of IMP infusion.
A Cardioscreen 1000 (Medis, Germany) was used for
non-invasive measurement of cardiac output (CO (L/
min) = heart rate × stroke volume / 1000), CI (L/min/
m2) and SVRI (dyne·s·cm5·m2) by the bio-impedence
technique before and after 120min of IMP infusion.
Similarly, arterial function was measured using an Arter-
iograph device (TensioMed, Hungary). Arterial stiffness
and central haemodynamics were assessed by the appli-
cation of an inflatable cuff to the upper arm. The aortic
pulse wave velocity (APWV, m/s) was calculated as the
distance the pulse wave travels in the aorta (as measured
from the suprasternal notch to pubic bone) divided by
the measured transit time.
Participants were monitored for 4 h after IMP discon-
tinuation and removal of the catheter and introducer
from the femoral vein. Vital signs were recorded every
30 min throughout the infusion and recovery periods,
with regular ECG monitoring. Adverse events (AEs)
were collected during visit 2 and by follow-up telephone
calls at 24 h and 4 weeks. The severity, expectedness and
causality of AEs in relation to the study medication were
noted by the study team. The Investigators and the co-
sponsors had the right at any time to terminate the
study for clinical or administrative reasons.
Statistical analysis
Analysis was per protocol. The number of participants
who were withdrawn by the investigator during the
course of the study is presented broken down by treat-
ment allocation and presented with reasons for with-
drawal where available. Missing data as a result of
patients not having the post-baseline measurement were
not imputed. Patients with missing post-baseline data
were excluded from the analysis at that time point.
Summary statistics (n, mean, SD, median, minimum,
maximum, Q1 and Q3) were generated over time for the
baseline, post-baseline and change from baseline mea-
surements for the primary endpoint in the serelaxin and
placebo group. The geometric mean was calculated for
the baseline value, the post-baseline values and the ratio
to the baseline values. Confidence intervals were calcu-
lated for both the arithmetic and geometric means.
Paired t tests were used to test the mean change from
baseline measurements. The secondary endpoints were
subjected to the same analysis as the HVPG. For the pla-
cebo control group, the change from baseline to 2 h was
analysed in the same way as the primary outcome, al-
though, as this was not powered for, no direct statistical
comparison was made between serelaxin and placebo.
There were no planned interim analyses for safety or
efficacy. All participants were analysed in the group to
which they were originally assigned irrespective of the
treatment received, with the exception of AEs which are
presented according to allocated treatment and also
treatment received. For all analyses, unless otherwise
specified, statistical significance was taken to be p < 0.05.
Results
Participant flow
Participant disposition is shown in the CONSORT dia-
gram (Fig. 1). A total of 17 participants were recruited.
Of these, two participants had a screening failure and
did not proceed to randomisation. Fifteen patients were
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randomised and 11 completed the trial (n = 9 serelaxin,
n = 2 placebo). Four participants were withdrawn by the
investigators following randomisation, did not receive
any study drug and are not included in any primary or
secondary analyses. Reasons for withdrawal were base-
line HVPG < 10mmHg (n = 2) and HVPG technical fail-
ure (n = 2). The trial ended early due to manufacturer
discontinuation of the study drug.
Baseline participant data
Participant characteristics are summarised in Table 1.
The median age of participants was 56 (range 43–69)
years and 73% were male. Cirrhosis aetiologies were
alcohol-related liver disease (n = 10), non-alcoholic fatty
liver disease (n = 2), chronic hepatitis C (n = 2) and
chronic hepatitis B (n = 1). Participants were Child–
Pugh class A (60%) and class B (40%) with a median
MELD score of 10 (range 6–14). The mean baseline
HVPG was 16.3 (range 10.3–21.7) mmHg.
Primary endpoint
In those allocated to the serelaxin arm (n = 11), two partic-
ipants were withdrawn. The arithmetic mean ± SD HVPG
at baseline was 15.9 ± 3.3mmHg compared to 15.6 ± 4.3
mmHg after 2 h of serelaxin infusion. Although individual
responses were variable (Fig. 2), there was no evidence of a
significant change in the fasting HVPG between the base-
line and 2 h time point (arithmetic mean of difference ±
SD was 0.4 ± 3.5mmHg (95% CI –2.3, 3.1; p = 0.76). In the
two placebo-treated patients, the HVPG decreased over
the 2-h observation period, but no further analysis or con-
clusions can be made in such a small sample (Table 2).
Secondary endpoints
There was no evidence of a significant change in fasting
HVPG between baseline (15.6 ± 3.3 mmHg) and 1 h of
serelaxin infusion (15.8 ± 2.1mmHg; p = 0.63). However,
five participants did not have HVPG measurements taken
at the 1-h time point. This was due to a decision by the
Fig. 1 Consort flow diagram. HVPG hepatic venous pressure gradient, QTc corrected QT interval
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study team to focus efforts on maintaining the catheter
position for the critical 2-h HVPG measurement (primary
endpoint).
For all of the other secondary endpoints, which were
measured after 2 h of serelaxin infusion (including HBF,
IVCP, CI, SVRI and APWV), no substantial changes
were observed (data summarised in Table 2).
Safety and tolerability of serelaxin
Treatment with serelaxin was well-tolerated. Overall, 12
AEs were reported in 7 participants treated with serelaxin
(Table 3). None were serious or considered related to the
IMP. There were no serious adverse events (SAEs) in this
study. No pregnancies were reported. There were no strik-
ing changes in laboratory blood tests monitored during
the course of the study (Table S1 in Additional file 2); in
particular, there were no newly occurring liver enzyme ab-
normalities observed. According to the product label,
hypotension is a potential side effect of serelaxin. Patients
with cirrhosis and PH often have lower baseline blood
pressure levels, predominantly due to severe splanchnic
vasodilatation. Following serelaxin, we observed a statisti-
cally significant increase in the heart rate (baseline 65 ± 8
bpm vs 2-h post serelaxin 72 ± 8 bpm, p = 0.02) and de-
crease in the mean arterial pressure (baseline 93 ± 7
mmHg vs 2-h post serelaxin 88 ± 5, p = 0.02) due to a re-
duction in diastolic rather than systolic blood pressure
(Table S2 in Additional file 2). However, changes were not
clinically significant and there were no discontinuations
due to tachycardia or hypotension.
Table 1 Summary of participant characteristics
All participants (n = 15) Serelaxin (n = 11) Placebo (n = 4)
Age (years) 56 (43–69) 56 (43–69) 59 (54–63)
Gender (% male) 11 (73%) 8 (73%) 3 (75%)
Ethnicity (% Caucasian) 15 (100%) 11 (100%) 4 (100%)
Aetiology of cirrhosis
Alcohol alone 10 (67%) 8 (73%) 2 (50%)
NAFLD 2 (13%) 1 (9%) 1 (25%)
HCV alone 1 (7%) 1 (9%) 0
HCV + HBV 1 (7%) 0 1 (25%)
Cryptogenic 1 (7%) 1 (9%) 0
Child–Pugh class A 9 (60%) 6 (54%) 3 (75%)
Child–Pugh class B 6 (40%) 5 (45%) 1 (25%)
Child–Pugh class C 0 0 0
Current/previous liver-related complications
Ascites 8 (53%) 6 (55%) 2 (50%)
Spontaneous bacterial peritonitis 0 0 0
Hepatic encephalopathy 4 (27%) 3 (27%) 1 (25%)
Variceal bleeding 5 (33%) 5 (45%) 0
BMI (kg/m2) 27.6 (19.8–36.6) 28.0 (24.1–36.6) 26.5 (19.8–31.8)
Systolic BP (mmHg) 145 (112–173) 155 (126–173) 134 (112–149)
Heart rate (bpm) 71 (46–97) 73 (46–97) 69 (66–71)
MELD score 10 (6–14) 11 (8–14) 7.5 (6–11)
Total bilirubin (μmol/L) 24 (6–44) 28 (7–44) 12 (6–17)
INR 1.2 (1.0–1.6) 1.3 (1.1–1.6) 1.2 (1–1.5)
Albumin (g/dL) 34 (23–40) 34 (23–39) 36 (30–40)
Platelet count (× 109/L) 71 (26–331) 71 (26–182) 104 (55–331)
AST (U/L) 43 (22–122) 46 (25–122) 28 (22–32)
ALT (U/L) 37 (10–123) 37 (12–123) 26 (10–39)
Ongoing alcohol use
Yes 4 (27%) 3 (27%) 1 (25%)
Data presented as median (range) or n (%)
ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, BP blood pressure, bpm beats per minute, HBV hepatitis B virus, HCV hepatitis
C virus, INR international normalised ratio, MELD model for end-stage liver disease, NAFLD non-alcoholic fatty liver disease
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Discussion
In this study, the vasoactive peptide molecule serelaxin (a
recombinant form of human relaxin-2) had a neutral ef-
fect on the HVPG and a range of secondary haemo-
dynamic endpoints in a population of patients with CSPH
(HVPG > 10mmHg). It is important to note that the trial
was terminated before the recruitment target was met;
consequently, although there was no overall reduction in
the HVPG observed in the serelaxin-treated sample, low
statistical power increases the probability of a type II error.
However, a consistent finding in this study and previous
studies is the good safety profile of serelaxin in patients
with liver cirrhosis. With 2 h of serelaxin infusion, there
were no newly occurring liver enzyme abnormalities, no
clinically significant changes in blood pressure and no dis-
continuations due to AEs. Additionally, in a separate
study, the pharmacokinetic and safety profiles of serelaxin
were not affected in patients with mild, moderate or se-
vere hepatic impairment [12]. In contrast, terlipressin is
associated with a high risk of serious (particularly ischae-
mic) complications [17].
PH is the strongest predictor of decompensation and
death in patients with compensated cirrhosis [18] and the
major driver for serious complications such as variceal
bleeding, ascites and hepatic encephalopathy. At present,
non-selective beta-blockers, vasopressin analogues and
somatostatin analogues are the mainstay of drug treat-
ment for PH, but these strategies are suboptimal and only
target splanchnic hyperaemia. New therapeutic options,
particularly drugs that reduce increased intrahepatic vas-
cular resistance in cirrhosis, are needed. In preclinical
models, serelaxin decreased portal pressure through an in-
crease in intrahepatic nitric oxide (NO) signalling and a
reduction in hepatic stellate cell contractility [10]. In an
initial small (n = 6), exploratory, non-controlled, open-
label, phase 2 study, serelaxin induced a rapid and poten-
tially clinically significant reduction in directly measured
portal vein pressure (and portal pressure gradient) in pa-
tients with cirrhosis, PH and a TIPSS in situ [11].
But pathophysiological mechanisms of PH differ in pa-
tients with mild PH (HVPG > 5 mmHg but < 10mmHg)
compared to those with CSPH (HVPG > 10mmHg) [19].
In mild PH, the main mechanism driving raised portal
pressure is increased intrahepatic vascular resistance,
while in those with CSPH/varices, increased portal blood
flow plays a substantial role in perpetuating and exacer-
bating the portal hypertensive state. These pathophysio-
logical differences can influence drug efficacy, depending
on the stage of disease and the predominant mechanism
of action. For example, patients with mild PH have a sig-
nificantly lower response to non-selective beta-blockers,
Fig. 2 Fasting HVPG response to serelaxin. Lines represent individual
participant changes in HVPG following 2-h infusion of serelaxin (n =
9). Filled diamonds indicate the group mean at each time point.
HVPG hepatic venous pressure gradient, ns not significant
Table 2 Primary and secondary endpoints in participants receiving serelaxin
Change from baseline to 1 h Change from baseline to 2 h
HVPG (mmHg) HVPG
(mmHg)
HBF (ml/
min)
IVCP
(mmHg)
Cardiac index (L/
min/m2)
SVRI
(dyne·s·cm5·m2)
APWV
(m/s)
Mean ± SD pre serelaxin 15.9 ± 3.3 15.9 ± 3.3 1.5 ± 0.8 8.2 ± 3.4 3.8 ± 0.5 1716 ± 398 8.1 ± 1.4
Mean ± SD post serelaxin 15.9 ± 2.1 15.6 ± 4.3 1.2 ± 0.8 9.0 ± 2.4 4.1 ± 0.8 1605 ± 474 8.0 ± 2.1
Arithmetic mean of difference ±
SD (95% CI)
−0.4 ± 1.9
(−3.4, 2.6),
p = 0.69
0.4 ± 3.5
(−2.3, 3.1),
p = 0.76
−0.3 ± 0.3
(− 0.7,
0.1),
p = 0.15
0.4 ± 1.7
(1.7,
−1.2),
p = 0.58
−0.3 ± 0.7
(− 0.8, 0.3),
p = 0.28
111 ± 394
(− 192, 414),
p = 0.42
0.2 ± 0.7
(− 0.4,
0.8),
p = 0.49
Geometric mean of difference +
CV (95% CI)
1.0 + 0.1
(0.8, 1.2),
p = 0.63
1.0 + 0.2
(0.9, 1.2),
p = 0.68
0.8 + 0.2
(0.6, 1.1),
p = 0.15
1.0 + 0.1
(1.0, 1.1),
p = 0.27
1.0 + 0.1
(0.9, 1.1),
p = 0.44
1.0 + 0.0
(1.0, 1.0),
p = 0.32
1.0 + 0.0
(1.0, 1.1),
p = 0.19
Descriptive statistics for the change from baseline in the HVPG and other endpoints, and the results from paired-sample t tests using both the arithmetic mean
and the geometric mean
APWV aortic pulse wave velocity, CI confidence interval, CV coefficient of variation, HBF hepatic blood flow, HVPG hepatic venous pressure gradient, IVCP inferior
vena cava pressure, SD standard deviation, SVRI systemic venous resistance index
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which reduce portal inflow, compared to those with
CSPH/varices who exhibit a hyperdynamic systemic circu-
lation [20]. It is possible, given its proposed mechanism of
action in cirrhosis (decreased intrahepatic vascular resist-
ance secondary to increased NO bioavailability), that sere-
laxin may have a more pronounced effect on portal
pressure in patients with mild PH. We recruited patients
with HVPG > 10mmHg because these individuals are at
most risk of decompensation and a decrease in portal
pressure in this population would potentially lead to a re-
duction in clinically meaningful endpoints (e.g. develop-
ment of varices, variceal bleeding and ascites).
The acute haemodynamic effects of vasoactive drugs
(e.g. propranolol, terlipressin, octreotide) on portal
pressure have generally been demonstrated within 20
min after i.v. administration [8, 21]. Here, serelaxin was
administered over a relatively short time-frame (2 h), at
least in part because rapid changes in visceral blood
flow had been observed in a previous exploratory study
in a similar patient population (ClinicalTrials.gov iden-
tifier: NCT01640964;). However, for drugs acting on
intrahepatic vascular resistance, previous studies have
been much longer (e.g. simvastatin significantly de-
creased the HVPG after 28 days of oral administration)
[22]. So, it is conceivable that potential changes in the
HVPG due to a reduction in intrahepatic vascular re-
sistance and/or anti-fibrotic/anti-inflammatory mecha-
nisms were not captured after only a short serelaxin
infusion. Whether any portal pressure reducing-effect
of serelaxin might be demonstrated after prolonged ad-
ministration would need to be verified in a longer, ad-
equately designed study, if formulation or half-life
issues can be resolved to enable chronic exposure to
recombinant human relaxin-2 (or alternative relaxin
family peptide receptor 1 (RXFP-1) agonist).
Limitations of the study
The main limitation is that the study was terminated be-
fore the recruitment target was met due to slow enrol-
ment and, ultimately, a global drug supply issue (Novartis
stopped manufacturing serelaxin and there was none
available with a shelf-life beyond 31 August 2018). There-
fore, based on the sample size calculation, the study is
underpowered to detect the primary endpoint. The study
was double-blind and placebo-controlled, which would
have addressed potential sources of bias. A formal dose-
ranging study of serelaxin in cirrhosis patients has not yet
been undertaken. We used the same infusion regimen that
had previously shown encouraging haemodynamic effects
[23] and had achieved similar steady-state serum concen-
trations to that observed in our 72-h rat cirrhosis models
[10] and in human heart failure following 48 h of i.v. sere-
laxin infusion [24]. However, the biological effects of re-
laxin are known to follow a U-shaped dose–response
curve [25] and we do not know whether serelaxin might
have induced more pronounced effects on the HVPG or
secondary haemodynamic endpoints at higher (or lower)
doses. Any future work on relaxin effects in cirrhosis
should address dose–response relationships.
Conclusions
In the first randomised controlled trial of serelaxin in
patients with liver cirrhosis, an i.v. infusion of serelaxin
for 2 h was safe and well-tolerated but caused no signifi-
cant reduction in portal pressure in participants with
CSPH (HVPG > 10mmHg).
Table 3 Adverse events
SN IMP Adverse event SAE/SAR Severity Relatedness to IMP Expectedness
002 Placebo Diarrhoea No Mild N/A N/A
003 Serelaxin Syncope on inserting Venflon No Mild Unrelated Unexpected
003 Serelaxin Syncope on inserting hepatic venous catheter No Mild Unrelated Unexpected
003 Serelaxin Syncope on removing hepatic venous catheter No Mild Unrelated Unexpected
003 Serelaxin Right upper-quadrant ache reported at 24 h follow-up No Mild Unrelated Unexpected
005 Serelaxin Mean diastolic BP < 60mmHg (58.3 mmHg at IMP + 30 min) No Mild Possibly related Expected
006 Serelaxin Prolonged QTc on ECG after 2 h of serelaxin infusion No Mild Possibly related Unexpected
008 Serelaxin Bilirubin rise No Mild Unrelated Unexpected
012 Serelaxin Prolonged QTc on ECG during recovery period
(normal throughout infusion)
No Mild Possibly related Unexpected
014 Serelaxin Syncope on inserting Venflon No Mild Unrelated Unexpected
014 Serelaxin Syncope on inserting hepatic venous catheter No Mild Unrelated Unexpected
014 Serelaxin Dental abscess No Mild Unrelated Unexpected
016 Serelaxin Femoral artery puncture No Mild Unrelated Unexpected
BP blood pressure, ECG electrocardiogram, IMP investigational medicinal product, N/A not applicable, QTc corrected QT interval, SAE serious adverse event, SAR
serious adverse reaction, SN study participant number
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